

ProteoTech to Present at
the Alzheimer's Association International Conference (AAIC)[®]
Copenhagen, Denmark, July 12-17, 2014

Kirkland, WA, July 15, 2014 – [ProteoTech, Inc.](#), announced today that Dr. Qubai Hu, Director of Molecular Biology, will present at the [Alzheimer's Association International Conference \(AAIC\)[®]](#) to be held in Copenhagen, Denmark at the Bella Center, July 12-17, 2014. Dr. Hu will present on Wednesday, July 16 and her presentation is entitled:

“Identification of Novel Small Molecule Tau Aggregation Inhibitors for Treatment of Tauopathies”

ProteoTech identified and validated at least [five unique lead small molecule compounds](#) (that represent new chemical entities) that potently inhibited tau proteins to form β -sheet-containing fibrils, and/or disrupted preformed tau fibrils *in vitro*. The inhibitory potency of these select lead compounds appeared to be better than those of previously reported chemical classes in the literature. Select ProteoTech lead compounds and back-ups have also been screened for pharmacokinetic profile and blood-brain-barrier penetration after peripheral administration in mice. Many of the lead compounds demonstrate adequate brain exposure. The lead compounds (including PTI-51-CH3 and PTI-80) are in development for potent inhibition and disruption of tau protein tangles, a key pathological hallmark in Alzheimer's disease and other tauopathies such as the rare “orphan” disease Progressive Supranuclear Palsy (PSP).

Dr. Alan Snow, President and Chief Scientific Officer of ProteoTech commented, “ProteoTech is extremely pleased to be selected by the Alzheimer's Association, to have Dr. Hu present this important work at their international conference. We believe the discovery and development of these compounds by ProteoTech is a significant advancement towards the potential future treatment of tauopathies such as Alzheimer's disease and PSP.”

About ProteoTech: ProteoTech is a privately-held, therapeutic development company that utilizes its amyloid expertise to discover and develop new drugs for treating misfolded protein disorders and amyloid diseases. ProteoTech's lead small molecule compound, [Systebryl[™] \(PTI-110\)](#) will soon be entering a Phase 1/2 proof-of-concept clinical trial in patients with AL (immunoglobulin light chain) amyloidosis (an “orphan” disease). Other drugs in the ProteoTech pipeline, include a small molecule drug inhibitor for TTR (transthyretin) amyloidosis, a small molecule drug inhibitor of alpha-synuclein accumulation (for Multiple System Atrophy and other synucleinopathies such as Parkinson's disease), and a small molecule drug that works on both the beta-amyloid protein and tau protein aggregates involved in Alzheimer's disease. For further information, please contact Dr. Roger Flugel, Chief Business Officer

(flugel@proteotech.com) or Dr. Alan Snow, President & Chief Scientific Officer
(snow@proteotech.com).